This immunosuppressant from Laboratorios Raam de Sahuayo, is supplied to patients with liver, kidney and/or heart transplants to prevent organ rejection. This health authority has 56 reports indicating a low concentration of tacrolimus in the blood indicating its therapeutic ineffectiveness.
Given the risks to the health of transplant patients, this health authority, in strict adherence to articles 397, 404 sections X, XII and XIII and 414 of the General Health Law, orders health professionals not to continue using or prescribing plus Octralin in its two presentations of 1.0 mg and 5.0 mg, until this health authority concludes the investigation.
Cofepris recommends to patients that, in the event of being treated with tacrolimus from Laboratorios Raam de Sahuayo, they see their doctor to seek therapeutic alternatives that do not put their health at risk.
Medical personnel must notify adverse reactions and discomforts after the supply of Octralin through the email: [email protected] or through the Cofepris page.
